Intrexon Corp (NYSE:XON) CEO Randal J. Kirk acquired 1,257,727 shares of the company’s stock in a transaction dated Wednesday, May 15th. The shares were bought at an average price of $4.40 per share, for a total transaction of $5,533,998.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of XON traded down $0.07 during mid-day trading on Thursday, reaching $4.66. The stock had a trading volume of 55,735 shares, compared to its average volume of 2,435,780. Intrexon Corp has a 12 month low of $3.95 and a 12 month high of $19.94.

Intrexon (NYSE:XON) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.28). The business had revenue of $23.30 million for the quarter, compared to analysts’ expectations of $32.12 million. Intrexon’s revenue for the quarter was down 41.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.36) EPS.

XON has been the subject of several recent research reports. Zacks Investment Research downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Monday, January 21st. Northland Securities downgraded shares of Intrexon from an “outperform” rating to a “market perform” rating in a research report on Friday, March 1st. Finally, JMP Securities restated a “buy” rating and set a $43.00 price target on shares of Intrexon in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $28.60.

A number of institutional investors have recently modified their holdings of XON. Third Security LLC lifted its position in shares of Intrexon by 1.0% during the fourth quarter. Third Security LLC now owns 67,688,170 shares of the biotechnology company’s stock valued at $442,681,000 after buying an additional 694,531 shares during the last quarter. First Trust Advisors LP raised its position in Intrexon by 72.6% during the 1st quarter. First Trust Advisors LP now owns 11,227,790 shares of the biotechnology company’s stock worth $59,058,000 after buying an additional 4,721,782 shares during the last quarter. BlackRock Inc. raised its position in Intrexon by 31.3% during the 4th quarter. BlackRock Inc. now owns 6,590,663 shares of the biotechnology company’s stock worth $43,103,000 after buying an additional 1,572,900 shares during the last quarter. Vanguard Group Inc raised its position in Intrexon by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 6,204,864 shares of the biotechnology company’s stock worth $106,847,000 after buying an additional 81,918 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Intrexon by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,204,864 shares of the biotechnology company’s stock worth $106,847,000 after purchasing an additional 81,918 shares during the period. Institutional investors own 84.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Intrexon Corp (XON) CEO Purchases $5,533,998.80 in Stock” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://theolympiareport.com/2019/05/16/intrexon-corp-xon-ceo-purchases-5533998-80-in-stock.html.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Article: How Does the Quiet Period Work?

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.